Spots Global Cancer Trial Database for Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
Official Title: Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
Study ID: NCT00591383
Conditions
Study Description
Brief Summary: Single arm, open label, Phase I, dose-escalation study of indibulin in combination with erlotinib in subjects with advanced histologically confirmed, solid tumors for which no standard therapy exists and for whom treatment with erlotinib is considered medically acceptable.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Houston, Texas, United States
Contact Details
Name: Jonathan Lewis, MD
Affiliation: Alaunos Therapeutics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
